Comparative Pharmacology
Head-to-head clinical analysis: FORTAZ versus KEFUROX IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORTAZ versus KEFUROX IN PLASTIC CONTAINER.
FORTAZ vs KEFUROX IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, leading to cell lysis.
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3 and PBP-1a/1b, leading to inhibition of transpeptidase activity and autolysin-mediated cell death.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day for serious infections.
750 mg to 1.5 g IV every 8 hours; for severe infections, up to 3 g IV every 8 hours.
None Documented
None Documented
2 hours (normal renal function); prolonged to 12-20 hours in ESRD
1.2-1.6 hours in adults with normal renal function. Extended to 15-22 hours in end-stage renal disease.
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; 5-10% biliary/fecal
Renal: 80-90% unchanged by glomerular filtration and tubular secretion. Biliary: <2% excreted in bile. Fecal: <1%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic